PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.11
D/E ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.06. Howard Marks would check for debt covenant compliance and refinancing risks.
-32.69
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 1.20. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
16.23
Coverage of 16.23 versus zero Drug Manufacturers - Specialty & Generic median interest expense. Walter Schloss would verify if our leverage provides advantages.
17.56
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.64. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
8.05%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.25%. Michael Burry would check for aggressive accounting and hidden risks.